30 Oct, 2019 09:37 AM
Noxopharm (ASX: NOX) today releases its Appendix 4C for the quarter ending 30 September 2019, as well as providing guidance for the next 12 months.
For more information, download the attached PDF...read more
28 Oct, 2019 09:18 AM
Noxopharm (ASX: NOX) announces that Dr Graham Kelly will assume the duties of interim CEO following the departure of former CEO, Dr Greg van Wyk.
While the Board understands that a dual CEO/Chair...read more
22 Oct, 2019 08:51 AM
Noxopharm (ASX: NOX) provides to the market the Noxopharm and Nyrada Inc corporate presentations ahead of the TechKnow Invest Roadshow 2019 in Sydney (October 22, 2019) and Melbourne (October 24, 20...read more
18 Oct, 2019 04:20 PM
Notice is hereby given that an Annual General Meeting of Shareholders of Noxopharm Limited ACN 608 966 123 will be held at 2:00PM AEDT on 20 November 2019 at Museum of Sydney, corner of Phillip and ...read more
18 Oct, 2019 03:06 PM
Potential for Fundamental Change in the Treatment of Brain Cancer
Noxopharm commences a research program pursuing a novel approach to the treatment of glioblastoma multiforme (GBM), the most...read more
02 Oct, 2019 11:41 AM
Noxopharm (ASX: NOX) is pleased to announce details of its 2019 Annual General Meeting to the market.
In addition to voting formalities, the Chair of the Board will present an overview of the yea...read more
24 Sep, 2019 02:15 PM
Noxopharm (ASX:NOX) announces today that Dr Greg Van Wyk is departing the business. Dr Van Wyk, who has been with Noxopharm for 10 months and was initially employed as its Chief Medical Officer, has...read more